employer coverage glp-1 news october 2025 GLP-1s and Obesity Coverage: Differing Perspectives for Employers and Health Plans Employers face rising costs and

Table of Contents Understanding Saxenda and Gastrointestinal Side Effects Saxenda (liraglutide 6 mg/mL) is a prescription medicine licensed in the UK for weight management in adults with obesity or those who are overweight with weight-related health conditions

They are documentation anchors

However, as we learn more about their role in treating skin conditions like hidradenitis suppurativa, psoriasis and others, dermatologists should consider getting more comfortable using them especially if the patient doesnt already have a specialist managing their metabolic health

However there is no established safety profile for GLP-1 in pregnancy and experts recommend discontinuing 1-2 months before conception